Effects of ICI 182780 in Advanced Breast Cancer
Author Information
Author(s): A Howell, D J DeFriend, J F R Robertson, R W Blamey, L Anderson, E Anderson, F A Sutcliffe, P Walton
Primary Institution: University of Manchester
Hypothesis
Can ICI 182780 be an effective treatment for advanced breast cancer resistant to tamoxifen?
Conclusion
ICI 182780 is an active second-line anti-oestrogen with a high response rate and long duration of effect in women with advanced breast cancer resistant to tamoxifen.
Supporting Evidence
- Thirteen (69%) patients responded to ICI 182780 after progression on tamoxifen.
- The median duration of response was 25 months.
- ICI 182780 did not induce significant side effects such as hot flushes or vaginal dryness.
- Serum levels of FSH and LH increased significantly during treatment.
Takeaway
This study tested a new medicine called ICI 182780 on women with breast cancer that didn't get better with another medicine. Most of the women felt better for a long time without many side effects.
Methodology
Nineteen post-menopausal women with advanced breast cancer resistant to tamoxifen were treated with ICI 182780 administered as a monthly depot intramuscular injection.
Potential Biases
Potential selection bias due to the specific inclusion criteria for participants.
Limitations
The study had a small sample size and was limited to post-menopausal women.
Participant Demographics
Nineteen post-menopausal women with advanced breast cancer.
Statistical Information
P-Value
p<0.005 for LH increase
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website